United Therapeutics Corporation (UTHR) United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP for Treatment of Acute Liver Failure
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Other Release
United Therapeutics Corporation (UTHR) Sec Form 8K
United Therapeutics Corporation (NASDAQ: UTHR) Sec Form 8K
Breaking News
United Therapeutics Corporation (UTHR) Surges 14.8% to $600.09
Insider confidence sends shares soaring. United Therapeutics Corporation surged 14.8% to $600.09 on Monday, March 30, 2026, after a wave of insider buying t...
United Therapeutics Corporation (UTHR) Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Other Release
ADVERTISEMENT
United Therapeutics Corporation (UTHR) United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Other Release
United Therapeutics Corporation (UTHR) Sec Form 8K
United Therapeutics Corporation (NASDAQ: UTHR) Sec Form 8K
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ: UTHR) Q4 2025 Earnings Call dated Feb. 25, 2026 Corporate Participants: Harry Silvers — Head of...
United Therapeutics Corporation (UTHR) United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Other Release
ADVERTISEMENT
United Therapeutics Corporation (UTHR) Sec Form 8K
United Therapeutics Corporation (NASDAQ: UTHR) Sec Form 8K
United Therapeutics Corporation (UTHR) Leerink Global Healthcare Conference
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Corporate Conference